127 related articles for article (PubMed ID: 11549101)
1. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.
Bekersky I; Fielding RM; Dressler DE; Kline S; Buell DN; Walsh TJ
J Clin Pharmacol; 2001 Sep; 41(9):963-71. PubMed ID: 11549101
[TBL] [Abstract][Full Text] [Related]
2. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
[TBL] [Abstract][Full Text] [Related]
4. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.
Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
Pharm Res; 1999 Nov; 16(11):1694-701. PubMed ID: 10571274
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.
Townsend RW; Zutshi A; Bekersky I
Drug Metab Dispos; 2001 May; 29(5):681-5. PubMed ID: 11302934
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
Matsui S; Imai S; Yabuki M; Komuro S
Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
Heinemann V; Bosse D; Jehn U; Kähny B; Wachholz K; Debus A; Scholz P; Kolb HJ; Wilmanns W
Antimicrob Agents Chemother; 1997 Jun; 41(6):1275-80. PubMed ID: 9174183
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
Bingöl B; Bakirel T
J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
[TBL] [Abstract][Full Text] [Related]
9. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.
Boswell GW; Bekersky I; Buell D; Hiles R; Walsh TJ
Antimicrob Agents Chemother; 1998 Feb; 42(2):263-8. PubMed ID: 9527770
[TBL] [Abstract][Full Text] [Related]
10. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
[TBL] [Abstract][Full Text] [Related]
12. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
[TBL] [Abstract][Full Text] [Related]
13. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.
Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
Pharm Res; 2000 Dec; 17(12):1494-502. PubMed ID: 11303959
[TBL] [Abstract][Full Text] [Related]
14. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.
Takemoto K; Kanazawa K
J Liposome Res; 2017 Sep; 27(3):186-194. PubMed ID: 27328721
[TBL] [Abstract][Full Text] [Related]
15. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Sci; 2005 Jan; 94(1):169-76. PubMed ID: 15761940
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
Ohata Y; Tomita Y; Suzuki K; Maniwa T; Yano Y; Sunakawa K
Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
[TBL] [Abstract][Full Text] [Related]
20. Bioanalysis of free and liposomal Amphotericin B in rat plasma using solid phase extraction and protein precipitation followed by LC-MS/MS.
Su C; Yang H; Sun H; Fawcett JP; Sun D; Gu J
J Pharm Biomed Anal; 2018 Sep; 158():288-293. PubMed ID: 29902693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
